Finding useful biomarkers for Parkinson s disease

Science Translational Medicine

Volumn 10, Issue 454, 2018, Pages

  Chen Plotkin, Alice S ^a   Albin, Roge ^b,c   Alcalay, Ro ^d   Babcock, Debr ^e   Bajaj, Vikra ^f   Bowman, Duboi ^g   Buko, Ale ^h   Cedarbaum, Jess ⁱ   Chelsky, Danie ^j   Cookson, Mar R ^k   Dawson, Te M ^l   Dewey, Richar ^m   Foroud, Tatian ⁿ   Frasier, Mar ^o   German, Dwigh ^p   Gwinn, Katrin ^e   Huang, Xueme ^q   Kopil, Catherin ^o   Kremer, Thoma ^r   Lasch, Shirle ^s   Marek, Ke ^s   Marto, Jarro A ^t,u   Merchant, Kalpan ^v   Mollenhauer, Bri ^w,x   Naito, Ann ^o   Potashkin, Judit ^y   Reimer, Alyss ^o   Rosenthal, Lian S ^l   Saunders Pullman, Rache ^z   Scherzer, Clemen R ^u   Sherer, Tod ^o   Singleton, Andre ^aa   Sutherland, Margare ^e   Thiele, Ine ^ab   Van Der Brug, Marce ^ac   Keuren Jensen, Kendall Van ^ad   Vaillancourt, Davi ^ae   Walt, Davi ^u   West, Andre ^af   Zhang, Jin ^ag   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Neurology Service and GRECC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f VERILY LIFE SCIENCES   (United States)

^g Columbia University ^*  (United States)

^h Keio University and Human Metabolome Technologies Inc   (United States)

ⁱ BIOGEN   (United States)

^j Montreal ^*  (Canada)

^k National Institute of Aging   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁿ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^p UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^q PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^r Pharmaceutical Research and Early Development   (Sweden)

^s INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^t HARVARD MEDICAL SCHOOL   (United States)

^u BRIGHAM AND WOMEN S HOSPITAL   (United States)

^v Chaperone Therapeutics   (Poland)

^w Paracelsus Elena Klinik   (Germany)

^x UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^y ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^z MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^aa NATIONAL INSTITUTE ON AGING   (United States)

^ab UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^ac GENENTECH INC   (United States)

^ad TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^ae UNIVERSITY OF FLORIDA   (United States)

^af The University of Alabama at Birmingham   (United States)

^ag UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; BIOLOGICAL MARKER;

AREA UNDER THE CURVE; DISEASE COURSE; ENZYME ACTIVITY; FOLLOW UP; GBA GENE; GENE MUTATION; HUMAN; INDUCED PLURIPOTENT STEM CELL; LRRK2 GENE; PARKINSON DISEASE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; REVIEW; SIGNAL NOISE RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SNCA GENE; STANDARDIZATION; UNIFIED PARKINSON DISEASE RATING SCALE; BLOOD; COHORT ANALYSIS; DISEASE EXACERBATION; PATHOLOGY; PRODROMAL SYMPTOM; STANDARD;

BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; PRODROMAL SYMPTOMS; REFERENCE STANDARDS;

EID: 85052005906     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aam6003     Document Type: Review

References (33)

1. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: Preferred definition and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001
2. C. H. Adler, T. G. Beach, J. G. Hentz, H. A. Shill, J. N. Caviness, E. Driver-Dunckley, M. N. Sabbagh, L. I. Sue, S. A. Jacobson, C. M. Belden, B. N. Dugger, Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study. Neurology 83, 406-412 (2014
3. K. Marek, D. Jennings, S. Lasch, A. Siderowf, C. Tanner, T. Simuni, C. Coffey, K. Kieburtz, E. Flagg, S. Chowdhury, W. Poewe, B. Mollenhauer, T. Sherer, M. Frasier, C. Meunier, A. Rudolph, C. Casaceli, J. Seibyl, S. Mendick, N. Schuff, Y. Zhang, A. Toga, K. Crawford, A. Ansbach, P. De Blasio, M. Piovella, J. Trojanowski, L. Shaw, A. Singleton, K. Hawkins, J. Eberling, D. Brooks, D. Russell, L. Leary, S. Factor, B. Sommerfeld, P. Hogarth, E. Pighetti, K. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629-635 (2011
4. Parkinson Study Group SURE-PD Investigators, M. A. Schwarzschild, A. Ascherio, M. F. Beal, M. E. Cudkowicz, G. C. Curhan, J. M. Hare, D. C. Hooper, K. D. Kieburtz, E. A. Macklin, D. Oakes, A. Rudolph, I. Shoulson, M. K. Tennis, A. J. Espay, M. Gartner, A. Hung, G. Bwala, R. Lenehan, E. Encarnacion, M. Ainslie, R. Castillo, D. Togasaki, G. Barles, J. H. Friedman, L. Niles, J. H. Carter, M. Murray, C. G. Goetz, J. Jaglin, A. Ahmed, D. S. Russell, C. Cotto, J. L. Goudreau, D. Russell, S. A. Parashos, P. Ede, M. H. Saint-Hilaire, C. A. Thomas, R. James, M. A. Stacy, J. Johnson, L. Gauger, J. Antonelle de Marcaida, S. Thurlow, S. H. Isaacson, L. Carvajal, J. Rao, M. Cook, C. Hope-Porche, L. McClurg, D. L. Grasso, R. Logan, C. Orme, T. Ross, A. F. Brocht, R. Constantinescu, S. Sharma, C. Venuto, J. Weber, K. Eaton, Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: A randomized clinical trial. JAMA Neurol. 71, 141-150 (2014
5. S. Lerche, I. Liepelt-Scarfone, G. Alves, P. Barone, S. Behnke, Y. Ben-Shlomo, H. Berendse, D. Burn, R. Dodel, D. Grosset, S. Heinzel, M. Hu, M. Kasten, R. Krüger, W. Maetzler, M. Moccia, B. Mollenhauer, W. Oertel, B. Roeben, U. Sunkel, U. Walter, K. Wirdefeldt, D. Berg, Methods in neuroepidemiology characterization of European longitudinal cohort studies in Parkinson s Disease-Report of the JPND Working Group BioLoC-PD. Neuroepidemiology 45, 282-297 (2015
6. L. S. Rosenthal, D. Drake, R. N. Alcalay, D. Babcock, F. D. Bowman, A. Chen-Plotkin, T. M. Dawson, R. B. Dewey Jr., D. C. German, X. Huang, B. Landin, M. McAuliffe, V. A. Petyuk, C. R. Scherzer, C. S. Hillaire-Clarke, B. A. Sieber, M. Sutherland, C. Tarn, A. West, D. Vaillancourt, J. Zhang, K. Gwinn; PDBP consortium, The NINDS Parkinson s Disease Biomarkers Program. Mov. Disord. 31, 915-923 (2016
7. U. J. Kang, J. G. Goldman, R. N. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, A. W. Amara, S. Frank, A. Rudolph, C. Casaceli, H. Andrews, K. Gwinn, M. Sutherland, C. Kopil, L. Vincent, M. Frasier, The BioFIND study: Characteristics of a clinically typical Parkinson s disease biomarker cohort. Mov. Disord. 31, 924-932 (2016)
8. T. G. Beach, C. H. Adler, L. I. Sue, G. Serrano, H. A. Shill, D. G. Walker, L. Lue, A. E. Roher, B. N. Dugger, C. Maarouf, A. C. Birdsill, A. Intorcia, M. Saxon-Labelle, J. Pullen, A. Scroggins, J. Filon, S. Scott, B. Hoffman, A. Garcia, J. N. Caviness, J. G. Hentz, E. Driver-Dunckley, S. A. Jacobson, K. J. Davis, C. M. Belden, K. E. Long, M. Malek-Ahmadi, J. J. Powell, L. D. Gale, L. R. Nicholson, R. J. Caselli, B. K. Woodruff, S. Z. Rapscak, G. L. Ahern, J. Shi, A. D. Burke, E. M. Reiman, M. N. Sabbagh, Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology 35, 354-389 (2015
9. B. Mollenhauer, E. Trautmann, F. Sixel-Döring, T. Wicke, J. Ebentheuer, M. Schaumburg, E. Lang, N. K. Focke, K. R. Kumar, K. Lohmann, C. Klein, M. G. Schlossmacher, R. Kohnen, T. Friede, C. Trenkwalder; DeNoPa Study Group, Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 81, 1226-1234 (2013
10. G. Alves, K. Brønnick, D. Aarsland, K. Blennow, H. Zetterberg, C. Ballard, M. W. Kurz, U. Andreasson, O.-B. Tysnes, J. P. Larsen, E. Mulugeta, CSF amyloid-and tau proteins, and cognitive performance, in early and untreated Parkinson s disease: The Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry 81, 1080-1086 (2010
11. M. Lawton, F. Baig, M. Rolinski, C. Ruffman, K. Nithi, M. T. May, Y. Ben-Shlomo, M. T. Hu, Parkinson s disease subtypes in the Oxford Parkinson Disease Centre (OPDC) discovery cohort. J. Parkinsons Dis. 5, 269-279 (2015
12. J. Sevigny, P. Chiao, T. Bussière, P. H. Weinreb, L. Williams, M. Maier, R. Dunstan, S. Salloway, T. Chen, Y. Ling, J. O Gorman, F. Qian, M. Arastu, M. Li, S. Chollate, M. S. Brennan, O. Quintero-Monzon, R. H. Scannevin, H. M. Arnold, T. Engber, K. Rhodes, J. Ferrero, Y. Hang, A. Mikulskis, J. Grimm, C. Hock, R. M. Nitsch, A. Sandrock, The antibody aducanumab reduces A? plaques in Alzheimer s disease. Nature 537, 50-56 (2016
13. R. A. Sperling, D. M. Rentz, K. A. Johnson, J. Karlawish, M. Donohue, D. P. Salmon, P. Aisen, The A4 study: Stopping AD before symptoms begin? Sci. Transl. Med. 6, 228fs13 (2014
14. R. B. Postuma, D. Aarsland, P. Barone, D. J. Burn, C. H. Hawkes, W. Oertel, T. Ziemssen, Identifying prodromal Parkinson s disease: Pre-motor disorders in Parkinson s disease. Mov. Disord. 27, 617-626 (2012
15. A. Siderowf, D. Jennings, S. Eberly, D. Oakes, K. A. Hawkins, A. Ascherio, M. B. Stern, K. Marek; PARS Investigators, Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov. Disord. 27, 406-412 (2012
16. J. K. Qiang, Y. C. Wong, A. Siderowf, H. I. Hurtig, S. X. Xie, V. M. Lee, J. Q. Trojanowski, D. Yearout, J. Leverenz, T. J. Montine, M. Stern, S. Mendick, D. Jennings, C. Zabetian, K. Marek, A. S. Chen-Plotkin, Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann. Neurol. 74, 119-127 (2013
17. L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C. M. Clark, P. S. Aisen, R. C. Petersen, K. Blennow, H. Soares, A. Simon, P. Lewczuk, R. Dean, E. Siemers, W. Potter, V. M. Lee, J. Q. Trojanowski; Alzheimer s Disease Neuroimaging Initiative, Cerebrospinal fluid biomarker signature in Alzheimer s disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413 (2009
18. B. L. Reijs, C. E. Teunissen, N. Goncharenko, F. Betsou, K. Blennow, I. Baldeiras, F. Brosseron, E. Cavedo, T. Fladby, L. Froelich, T. Gabryelewicz, H. Gurvit, E. Kapaki, P. Koson, L. Kulic, S. Lehmann, P. Lewczuk, A. Lleó, W. Maetzler, A. de Mendonca, A. M. Miller, J. L. Molinuevo, B. Mollenhauer, L. Parnetti, U. Rot, A. Schneider, A. H. Simonsen, F. Tagliavini, M. Tsolaki, M. M. Verbeek, F. R. Verhey, M. Zboch, B. Winblad, P. Scheltens, H. Zetterberg, P. J. Visser, The central biobank and virtual biobank of BIOMARKAPD: A resource for studies on neurodegenerative diseases. Front. Neurol. 6, 216 (2015
19. L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka, M. Figurski, E. Coart, K. Blennow, H. Soares, A. J. Simon, P. Lewczuk, R. A. Dean, E. Siemers, W. Potter, V. M. Lee, J. Q. Trojanowski; Alzheimer s Disease Neuroimaging Initiative, Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 121, 597-609 (2011
20. L. Parnetti, A. Castrioto, D. Chiasserini, E. Persichetti, N. Tambasco, O. El-Agnaf, P. Calabresi, Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 9, 131-140 (2013
21. A. S. Chen-Plotkin, Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 84, 594-607 (2014
22. B. Mollenhauer, L. Rochester, A. Chen-Plotkin, D. Brooks, What can biomarkers tell us about cognition in Parkinson s disease? Mov. Disord. 29, 622-633 (2014)
23. A. H. Simonsen, B. Kuiperij, O. M. El-Agnaf, S. Engelborghs, S. K. Herukka, L. Parnetti, I. Rektorova, E. Vanmechelen, E. Kapaki, M. Verbeek, B. Mollenhauer, The utility of-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. Biomark. Med. 10, 19-34 (2016
24. M. Shi, J. Movius, R. Dator, P. Aro, Y. Zhao, C. Pan, X. Lin, T. K. Bammler, T. Stewart, C. P. Zabetian, E. R. Peskind, S. C. Hu, J. F. Quinn, D. R. Galasko, J. Zhang, Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: A staged pipeline for discovery and validation. Mol. Cell. Proteomics 14, 544-555 (2015
25. S. E. O Bryant, G. Xiao, F. Zhang, M. Edwards, D. C. German, X. Yin, T. Como, J. Reisch, R. M. Huebinger, N. Graff-Radford, D. Dickson, R. Barber, J. Hall, P. O Suilleabhain, P. Grammas, Validation of a serum screen for Alzheimer s disease across assay platforms, species, and tissues. J. Alzheimers Dis. 42, 1325-1335 (2014
26. Y. Berlyand, D. Weintraub, S. X. Xie, I. A. Mellis, J. Doshi, J. Rick, J. McBride, C. Davatzikos, L. M. Shaw, H. Hurtig, J. Q. Trojanowski, A. S. Chen-Plotkin, An Alzheimer s disease-derived biomarker signature identifies Parkinson s disease patients with dementia. PLOS ONE 11, e0147319 (2016
27. M. A. Nalls, C. Y. McLean, J. Rick, S. Eberly, S. J. Hutten, K. Gwinn, M. Sutherland, M. Martinez, P. Heutink, N. M. Williams, J. Hardy, T. Gasser, A. Brice, T. R. Price, A. Nicolas, M. F. Keller, C. Molony, J. R. Gibbs, A. Chen-Plotkin, E. Suh, C. Letson, M. S. Fiandaca, M. Mapstone, H. J. Federoff, A. J. Noyce, H. Morris, V. M. Van Deerlin, D. Weintraub, C. Zabetian, D. G. Hernandez, S. Lesage, M. Mullins, E. D. Conley, C. A. Northover, M. Frasier, K. Marek, A. G. Day-Williams, D. J. Stone, J. P. Ioannidis, A. B. Singleton; Parkinson s Disease Biomarkers Program and Parkinson s Progression Marker Initiative investigators, Diagnosis of Parkinson s disease on the basis of clinical and genetic classification: A population-based modelling study. Lancet Neurol. 14, 1002-1009 (2015
28. C. A. Cooper, N. Jain, M. D. Gallagher, D. Weintraub, S. X. Xie, Y. Berlyand, A. J. Espay, J. Quinn, K. L. Edwards, T. Montine, V. M. Van Deerlin, J. Trojanowski, C. P. Zabetian, A. S. Chen-Plotkin, Common variant rs356182 near SNCA defines a Parkinson s disease endophenotype. Ann. Clin. Transl. Neurol. 4, 15-25 (2016
29. R. N. Alcalay, O. A. Levy, C. C. Waters, S. Fahn, B. Ford, S. H. Kuo, P. Mazzoni, M. W. Pauciulo, W. C. Nichols, Z. Gan-Or, G. A. Rouleau, W. K. Chung, P. Wolf, P. Oliva, J. Keutzer, K. Marder, X. Zhang, Glucocerebrosidase activity in Parkinson s disease with and without GBA mutations. Brain 138, 2648-2658 (2015
30. K. B. Fraser, M. S. Moehle, R. N. Alcalay, A. B. West; LRRK2 Cohort Consortium, Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology 86, 994-999 (2016
31. J. P. Ioannidis, Why most published research findings are false. PLOS Med. 2, e124 (2005)
32. C. R. Swanson, Y. Berlyand, S. X. Xie, R. N. Alcalay, L. M. Chahine, A. S. Chen-Plotkin, Plasma apolipoprotein A1 associates with age at onset and motor severity Parkinson s disease patients. Mov. Discord. 30, 1648-1656 (2015
33. B. Freidlin, E. L. Korn, Biomarker enrichment strategies: Matching trial design to biomarker credentials. Nat. Rev. Clin. Oncol. 11, 81-90 (2014